CellaVision AB qualified for trade on the new NASDAQ OMX First North Premier

The listing on First North Premier requires the company to comply with higher disclosure and accounting standards than the regular First North rules. This imposes higher demands on transparency which brings benefits to both listed companies and investors.

 

During the last five years CellaVision has been showing strong sales growth and the company reported positive result for the first time for the year 2007. The hospital demand for efficiency is a strong driving force, and the customer base today consists of laboratories mainly in Europe and North America.

 

CellaVision shares will be traded using the short name CEVI. Certified Adviser for CellaVision is Remium AB.

 

 

Yvonne Mårtensson, CEO, CellaVision AB

Phone: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com

 

Lars Gatenbeck, Chairman of the Board, CellaVision AB
Phone: +46 705 35 44 44. E-mail: lars.gatenbeck@GZgroup.se

 

 

CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.

 

The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.

 

CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.